These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 22698482

  • 1. The neuroprotective effect of the GSK-3β inhibitor and influence on the extrinsic apoptosis in the ALS transgenic mice.
    Ahn SW, Kim JE, Park KS, Choi WJ, Hong YH, Kim SM, Kim SH, Lee KW, Sung JJ.
    J Neurol Sci; 2012 Sep 15; 320(1-2):1-5. PubMed ID: 22698482
    [Abstract] [Full Text] [Related]

  • 2. Neuroprotective effects of JGK-263 in transgenic SOD1-G93A mice of amyotrophic lateral sclerosis.
    Ahn SW, Jeon GS, Kim MJ, Shon JH, Kim JE, Shin JY, Kim SM, Kim SH, Ye IH, Lee KW, Hong YH, Sung JJ.
    J Neurol Sci; 2014 May 15; 340(1-2):112-6. PubMed ID: 24680562
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of glycogen synthase kinase-3 suppresses the onset of symptoms and disease progression of G93A-SOD1 mouse model of ALS.
    Koh SH, Kim Y, Kim HY, Hwang S, Lee CH, Kim SH.
    Exp Neurol; 2007 Jun 15; 205(2):336-46. PubMed ID: 17433298
    [Abstract] [Full Text] [Related]

  • 4. Extrinsic Apoptosis Pathway Altered by Glycogen Synthase Kinase-3β Inhibitor Influences the Net Drug Effect on NSC-34 Motor Neuron-Like Cell Survival.
    Kim JE, Lim JH, Jeon GS, Shin JY, Ahn SW, Kim SH, Lee KW, Hong YH, Sung JJ.
    Biomed Res Int; 2017 Jun 15; 2017():4163839. PubMed ID: 29082245
    [Abstract] [Full Text] [Related]

  • 5. Role of GSK-3beta activity in motor neuronal cell death induced by G93A or A4V mutant hSOD1 gene.
    Koh SH, Lee YB, Kim KS, Kim HJ, Kim M, Lee YJ, Kim J, Lee KW, Kim SH.
    Eur J Neurosci; 2005 Jul 15; 22(2):301-9. PubMed ID: 16045483
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Guanabenz delays the onset of disease symptoms, extends lifespan, improves motor performance and attenuates motor neuron loss in the SOD1 G93A mouse model of amyotrophic lateral sclerosis.
    Jiang HQ, Ren M, Jiang HZ, Wang J, Zhang J, Yin X, Wang SY, Qi Y, Wang XD, Feng HL.
    Neuroscience; 2014 Sep 26; 277():132-8. PubMed ID: 24699224
    [Abstract] [Full Text] [Related]

  • 8. Activation of the stress-activated MAP kinase, p38, but not JNK in cortical motor neurons during early presymptomatic stages of amyotrophic lateral sclerosis in transgenic mice.
    Holasek SS, Wengenack TM, Kandimalla KK, Montano C, Gregor DM, Curran GL, Poduslo JF.
    Brain Res; 2005 May 31; 1045(1-2):185-98. PubMed ID: 15910777
    [Abstract] [Full Text] [Related]

  • 9. Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis.
    Takata M, Tanaka H, Kimura M, Nagahara Y, Tanaka K, Kawasaki K, Seto M, Tsuruma K, Shimazawa M, Hara H.
    Br J Pharmacol; 2013 Sep 31; 170(2):341-51. PubMed ID: 23763343
    [Abstract] [Full Text] [Related]

  • 10. Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation.
    Peviani M, Salvaneschi E, Bontempi L, Petese A, Manzo A, Rossi D, Salmona M, Collina S, Bigini P, Curti D.
    Neurobiol Dis; 2014 Feb 31; 62():218-32. PubMed ID: 24141020
    [Abstract] [Full Text] [Related]

  • 11. Neuroprotective Effect of Human Adipose Stem Cell-Derived Extract in Amyotrophic Lateral Sclerosis.
    Jeon GS, Im W, Shim YM, Lee M, Kim MJ, Hong YH, Seong SY, Kim M, Sung JJ.
    Neurochem Res; 2016 Apr 31; 41(4):913-23. PubMed ID: 26646002
    [Abstract] [Full Text] [Related]

  • 12. Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model.
    Feng HL, Leng Y, Ma CH, Zhang J, Ren M, Chuang DM.
    Neuroscience; 2008 Aug 26; 155(3):567-72. PubMed ID: 18640245
    [Abstract] [Full Text] [Related]

  • 13. Recombinant human erythropoietin suppresses symptom onset and progression of G93A-SOD1 mouse model of ALS by preventing motor neuron death and inflammation.
    Koh SH, Kim Y, Kim HY, Cho GW, Kim KS, Kim SH.
    Eur J Neurosci; 2007 Apr 26; 25(7):1923-30. PubMed ID: 17439481
    [Abstract] [Full Text] [Related]

  • 14. c-Abl inhibition delays motor neuron degeneration in the G93A mouse, an animal model of amyotrophic lateral sclerosis.
    Katsumata R, Ishigaki S, Katsuno M, Kawai K, Sone J, Huang Z, Adachi H, Tanaka F, Urano F, Sobue G.
    PLoS One; 2012 Apr 26; 7(9):e46185. PubMed ID: 23049975
    [Abstract] [Full Text] [Related]

  • 15. Tideglusib, a Non-ATP Competitive Inhibitor of GSK-3β as a Drug Candidate for the Treatment of Amyotrophic Lateral Sclerosis.
    Martínez-González L, Gonzalo-Consuegra C, Gómez-Almería M, Porras G, de Lago E, Martín-Requero Á, Martínez A.
    Int J Mol Sci; 2021 Aug 20; 22(16):. PubMed ID: 34445680
    [Abstract] [Full Text] [Related]

  • 16. Toll-Like Receptor-4 Inhibitor TAK-242 Attenuates Motor Dysfunction and Spinal Cord Pathology in an Amyotrophic Lateral Sclerosis Mouse Model.
    Fellner A, Barhum Y, Angel A, Perets N, Steiner I, Offen D, Lev N.
    Int J Mol Sci; 2017 Aug 01; 18(8):. PubMed ID: 28763002
    [Abstract] [Full Text] [Related]

  • 17. Immunohistochemical expression of IGF-I and GSK in the spinal cord of Kii and Guamanian ALS patients.
    Kihira T, Suzuki A, Kondo T, Wakayama I, Yoshida S, Hasegawa K, Garruto RM.
    Neuropathology; 2009 Oct 01; 29(5):548-58. PubMed ID: 19323791
    [Abstract] [Full Text] [Related]

  • 18. Loss of Fas ligand-function improves survival in G93A-transgenic ALS mice.
    Petri S, Kiaei M, Wille E, Calingasan NY, Flint Beal M.
    J Neurol Sci; 2006 Dec 21; 251(1-2):44-9. PubMed ID: 17049562
    [Abstract] [Full Text] [Related]

  • 19. n-butylidenephthalide treatment prolongs life span and attenuates motor neuron loss in SOD1G93A mouse model of amyotrophic lateral sclerosis.
    Zhou QM, Zhang JJ, Li S, Chen S, Le WD.
    CNS Neurosci Ther; 2017 May 21; 23(5):375-385. PubMed ID: 28229532
    [Abstract] [Full Text] [Related]

  • 20. Chronic treatment with lithium does not improve neuromuscular phenotype in a mouse model of severe spinal muscular atrophy.
    Dachs E, Piedrafita L, Hereu M, Esquerda JE, Calderó J.
    Neuroscience; 2013 Oct 10; 250():417-33. PubMed ID: 23876328
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.